Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Clareon ® Vivity ®, the first and only non-diffractive extended depth of focus intraocular ...

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Alcon’s ALC AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have recently surpassed more than one million implants worldwide.The company’s ...

Alcon, the global leader in eye care, announces that its AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants ...

Alcon ALC recently announced that its Clareon Vivity intraocular lens (IOL), featuring extended depth of focus (EDOF) technology, has received CE Mark approval. The lens, made from Alcon's ...

Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.

“The advanced technologies of PC-IOLs, such as Alcon’s Clareon® Vivity® and Clareon PanOptix® lenses, can be life-changing for people with cataracts,” said Vendal.

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments ...

We believe Alcon is in fine financial health. At the end of fiscal 2022, the company had roughly $1 billion in cash and equivalents and $4.5 billion of debt with 10% of its balance due to mature ...